Skip to content

Epidural Stimulation After Neurologic Damage

Epidural Stimulation for Spinal Cord Injury

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03026816
Acronym
E-STAND
Enrollment
100
Registered
2017-01-20
Start date
2017-08-07
Completion date
2028-01-31
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries, Paraplegia, Complete

Keywords

epidural stimulation, spinal cord stimulation, autonomic dysfunction

Brief summary

This study will evaluate a method to optimize parameter settings in epidural spinal cord stimulation used to recover lower extremity volitional movement. The study will also characterize improvement in autonomic function (such as blood pressure control) and other functions related to spinal cord injury.

Detailed description

Epidural spinal cord stimulation for the purpose of facilitating volitional movement is a new and novel neuromodulatory treatment. Epidural SCS has a long history of use for chronic pain with established medical device platforms. The purpose of this study is to investigate and establish the use of SCS for volitional movement. Specifically, establishing the disinhibitory effect of SCS in a greater population with inherent greater variability. In addition to establishing the disinhibitory effect of SCS for cSCI, our study attempts to explore the parameter space of the spinal cord stimulator platforms in order to optimize stimulation settings for patients through the creation of a clinical decision support system (CDSS). Preliminary evidence suggests benefit to autonomic function, and this study also begins to explore the effects of SCS on cardiovascular function, urinary function, psychiatric outcomes, and quality of life, which all offer significant potential for patients suffering from chronic spinal cord injury.

Interventions

epidural spinal cord stimulator

Sponsors

Minnesota Office of Higher Education
CollaboratorOTHER_GOV
Minneapolis Veterans Affairs Medical Center
CollaboratorFED
Hennepin Healthcare Research Institute
CollaboratorOTHER
Hennepin County Medical Center, Minneapolis
CollaboratorOTHER
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Masking is done during formal testing of BMCA

Intervention model description

All subjects will receive study intervention. Outcome assessments will be tested while the stimulator unit is on (intervention) and off (sham) during the study.

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 22 years of age or older * Able to undergo the informed consent/assent process * Stable, motor-complete paraplegia * Discrete spinal cord injury between C6 and T10 * ASIA A or B Spinal Cord Injury Classification * Medically stable in the judgement of the principal investigator * Intact segmental reflexes below the lesion of injury * Greater than 1 year since initial injury and at least 6 months from any required spinal instrumentation * Willing to attend all scheduled appointments

Exclusion criteria

* Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery (e.g. cardiopulmonary issues) * Inability to withhold antiplatelet/anticoagulation agents perioperatively * Significant dysautonomia that would prohibit rehabilitation or assisted standing or any history of CVA or MI associated with autonomic dysreflexia. A single tilt table test with syncope, presyncope, or SBP \< 50 or \>200. * Other conditions that would make the subject unable to participate in testing/rehabilitation in the judgement of the principal investigator * Current and anticipated need for opioid pain medications or pain that would prevent full participation in the rehabilitation program in the judgement of the principal investigator * Clinically significant mental illness in the judgement of the principal investigator * Botulinum toxin injections in the previous 6 months * Volitional movements present during EMG testing in bilateral lower extremities * Unhealed spinal fracture * Presence of significant contracture * Presence of pressure ulcers * Recurrent urinary tract infection refractory to antibiotics * Current Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in Volitional Response Index MagnitudeMonths: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15Brain Motor Control Assessment Volitional Response Index Magnitude

Secondary

MeasureTime frameDescription
Spinal cord stimulation for cardiovascular functionOver 12 monthsSystolic blood pressure measured during epidural stimulation (continuous)
Cerebrovascular Assessment ChangeMonths: 3, 6, 9Cerebral blood flow (CBF) during tilt table
Change in Visual Neurocognitive AssessmentMonths: 3, 6, 9Stroop Test
Spinal cord stimulation optimizationOver 12 monthsProbit preference response surface obtained by serial force binary choice

Countries

United States

Contacts

Primary ContactStudy Coordinator
estand@umn.edu612-873-9113
Backup ContactDavid Darrow, MD MPH
estand@umn.edu612-217-4290

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026